Last updated: August 28, 2026
Glyceryl mono- and dipalmitostearate is a lipid excipient used primarily in modified-release tablets, multiparticulate systems, lipid-based formulations, topical products and some nutraceutical dosage forms. Its commercial outlook is tied to pharmaceutical formulation outsourcing, oral controlled-release development, high-purity excipient demand and regional manufacturing costs rather than to a single branded product.
No major supplier publicly reports revenue for glyceryl mono- and dipalmitostearate as a standalone product. Public market estimates therefore vary widely and often combine pharmaceutical-grade material with food-grade E471, glyceryl monostearate, glyceryl palmitostearate and related glycerol fatty-acid esters. The most defensible financial view is directional: volume growth should remain steady, while pricing and margin performance will depend on purity, regulatory documentation, supply qualification and fatty-acid feedstock costs.
What is glyceryl mono- and dipalmitostearate?
Glyceryl mono- and dipalmitostearate is a mixture of glycerol esters containing palmitic and stearic acid residues. Commercial products can contain monoesters, diesters and closely related glycerides. The material is commonly associated with glyceryl palmitostearate, glyceryl stearate and glycerol fatty-acid esters.
Its functional value comes from its lipid matrix-forming properties. In pharmaceutical formulations, it can:
- Slow drug release through diffusion and erosion control.
- Improve tablet structure and compaction.
- Act as a carrier in lipid-based delivery systems.
- Modify wetting and dissolution.
- Support hot-melt or solvent-based multiparticulate processing.
- Improve consistency in topical and semisolid formulations.
The product is not an active pharmaceutical ingredient. Its value is determined by composition, melting behavior, particle size, peroxide value, residual solvents, microbial quality, trace metals, stability and batch-to-batch reproducibility.
Which pharmaceutical products use glyceryl mono- and dipalmitostearate?
Pharmaceutical applications are concentrated in oral solid dosage forms.
| Application |
Formulation role |
Commercial relevance |
| Sustained-release tablets |
Hydrophobic matrix former |
Core pharmaceutical use |
| Extended-release capsules |
Lipid carrier and release modifier |
Relevant in multiparticulate systems |
| Pellets and granules |
Coating or matrix component |
Used by contract manufacturers and specialty formulators |
| Lipid-based formulations |
Solubilization and carrier function |
Smaller but technically valuable segment |
| Topical and dermatological products |
Emollient, consistency agent and structuring lipid |
Stable demand |
| Nutraceutical tablets and capsules |
Lubricity and matrix control |
Larger-volume, lower-margin segment |
| Food and confectionery |
Emulsifier and texturizer |
Separate market, generally lower regulatory value |
Pharmaceutical formulators select the excipient when a controlled-release profile requires a hydrophobic matrix that is easier to process than some synthetic polymers. The material is often evaluated against glyceryl behenate, hydrogenated vegetable oils, stearic acid, carnauba wax, ethylcellulose and polymethacrylate systems.
How large is the glyceryl mono- and dipalmitostearate market?
A reliable standalone global market size is not publicly available. Industry reports frequently group the substance with broader categories, including:
- Glyceryl monostearate.
- Glyceryl palmitostearate.
- Glycerol monopalmitate.
- Glycerol esters of fatty acids.
- Pharmaceutical lubricants and release-modifying excipients.
- Food emulsifiers under E471.
This aggregation creates material uncertainty in market sizing. Pharmaceutical-grade revenue is likely a small fraction of the broader glycerol fatty-acid ester market, but it has higher average selling prices and stronger customer retention because excipient changes can trigger formulation, stability and regulatory work.
The economically relevant market is therefore better measured by qualified pharmaceutical volume and supplier revenue than by total global tonnage.
Indicative market structure
| Segment |
Volume profile |
Pricing profile |
Margin profile |
| Food-grade E471 |
High |
Low |
Low to moderate |
| Industrial-grade glycerides |
High |
Low |
Low |
| Nutraceutical grade |
Moderate |
Moderate |
Moderate |
| Pharmaceutical grade |
Lower |
Higher |
Moderate to high |
| Specialty controlled-release grades |
Lower |
Highest |
Highest |
A pharmaceutical-grade product can command a multiple of food-grade pricing because of tighter specifications, documentation, validated production, change-control obligations and customer qualification. The premium is not uniform. It depends on pharmacopeial compliance, manufacturing location, particle engineering and whether the product is sold as a branded excipient platform.
What is driving demand for glyceryl mono- and dipalmitostearate?
Growth in modified-release oral medicines
Modified-release tablets and multiparticulates remain the main demand driver. Developers use lipid matrices to reduce dosing frequency and manage drug exposure. Generic drug manufacturers also use established lipid excipients to reproduce reference-product dissolution profiles.
Demand is strongest where the excipient can provide:
- Robust release control across manufacturing scales.
- Acceptable tablet hardness and friability.
- Stable performance under accelerated conditions.
- Compatibility with high drug loading.
- A manageable regulatory package.
Expansion of generic and contract development manufacturing
Generic manufacturers and contract development and manufacturing organizations are important buyers. They often require multiple qualified sources, especially for products exposed to supply disruption or customer audit requirements.
Once an excipient is embedded in a regulated formulation, replacement can require comparative dissolution studies, stability work, process revalidation and, in some cases, regulatory filing updates. This creates switching costs that are higher than the underlying chemical complexity would suggest.
Growth in lipid-based formulation development
Lipid excipients are used in formulations for poorly water-soluble drugs. Glyceryl mono- and dipalmitostearate is not a universal solubilizer, but it can form part of structured lipid systems and solid lipid delivery platforms. This segment remains smaller than controlled-release oral solids but has higher technical value.
Regional pharmaceutical manufacturing
India and China continue to expand generic, contract manufacturing and formulation capacity. Europe and North America remain important for regulated supply, specialty excipient development and customer qualification. Regional demand is shaped by:
- Local availability of stearic and palmitic acid feedstocks.
- Import controls and freight costs.
- GMP inspection requirements.
- Customer preference for dual sourcing.
- Pharmacopoeial compliance.
- Capacity for technical support and regulatory documentation.
How do raw-material prices affect financial performance?
Glyceryl mono- and dipalmitostearate is exposed to the cost of vegetable oils, animal fats, palm-derived fatty acids, stearic acid, palmitic acid, glycerin, energy and packaging.
The principal cost variables are:
- Fatty-acid feedstock prices.
- Hydrogenation and fractionation costs.
- Energy consumption.
- Quality-control testing.
- Batch segregation and cleaning.
- Regulatory and audit costs.
- Freight and storage.
Food-grade producers can often pass through raw-material increases more quickly because contracts are volume-driven and specifications are less restrictive. Pharmaceutical suppliers have greater pricing power after qualification, but price increases can be delayed by annual contracts, customer approval procedures and competitive dual sourcing.
Margin expansion is most likely when suppliers move from bulk glycerides to higher-value pharmaceutical grades with:
- Narrower composition ranges.
- Controlled particle size.
- Lower impurity levels.
- Better dissolution reproducibility.
- Pharmacopeial compliance.
- Regulatory support packages.
- Technical formulation assistance.
Which companies supply pharmaceutical-grade material?
The competitive field includes specialty excipient manufacturers, lipid technology companies, oleochemical producers and regional pharmaceutical-material suppliers. Relevant supplier categories include:
| Supplier type |
Competitive advantage |
| Specialty excipient companies |
Formulation support, documentation and global regulatory coverage |
| Oleochemical manufacturers |
Feedstock integration and lower production cost |
| Regional excipient producers |
Local delivery, pricing and customer responsiveness |
| Lipid delivery specialists |
Technical know-how in modified release and poorly soluble drugs |
| Food-grade producers entering pharma |
Scale and lower cost, but potentially weaker pharmaceutical positioning |
Commercial products associated with glyceryl palmitostearate and related excipients include specialty grades marketed for sustained-release matrix systems. Gattefossé’s Precirol range is a prominent example of lipid excipients used in oral modified-release formulation development. Other suppliers may offer equivalent or near-equivalent glycerol fatty-acid ester grades under different specifications and trade names.
Supplier comparisons should focus on actual specification and regulatory documentation rather than chemical name alone. Two products described as glyceryl palmitostearate may differ in ester distribution, melting range, surface area, residual moisture and dissolution behavior.
What is the regulatory status of glyceryl mono- and dipalmitostearate?
Glyceryl mono- and dipalmitostearate is an excipient rather than an FDA-approved active drug. FDA’s Inactive Ingredient Database records excipient use by dosage form, route and maximum potency where data are available. The database does not constitute a blanket approval for every grade, supplier or formulation [1].
Pharmaceutical acceptability normally depends on:
- Compliance with the applicable USP-NF, Ph. Eur. or other recognized specification.
- Supplier GMP controls.
- Impurity and contaminant testing.
- Residual solvent controls.
- Elemental impurity assessment.
- Nitrosamine-risk evaluation where relevant to the manufacturing process.
- Stability and compatibility data in the finished dosage form.
- Adequate change-control procedures.
In Europe, excipient selection is assessed under the EU framework for excipients and pharmaceutical product quality. The European Commission has also developed risk-based expectations for excipient GMP, including the formal risk assessment described in Part I, Chapter 5 of the EU GMP Guide [2].
Food uses are regulated separately. Mono- and diglycerides of fatty acids are authorized in the European Union as food additive E471, subject to applicable purity and use requirements. The European Food Safety Authority completed a reevaluation of E471 and identified the need to distinguish food-use exposure and specifications from pharmaceutical applications [3].
What patents protect glyceryl mono- and dipalmitostearate?
The molecule class itself is not generally protected by a commercially meaningful, broad patent monopoly. It is a known glyceride excipient with long-standing food, cosmetic and pharmaceutical use.
Patent activity is more likely to concern:
- Specific controlled-release formulations.
- Drug-excipient ratios.
- Multiparticulate systems.
- Manufacturing processes.
- Particle-size engineering.
- Solid lipid nanoparticles.
- Combination excipient systems.
- Particular dosage forms or release profiles.
A formulation patent may claim a drug product containing glyceryl palmitostearate, but that does not create an exclusive right over the excipient as a commodity. Patent risk must be assessed at the finished-product level, not solely by searching the excipient name.
Orange Book and Paragraph IV status
Glyceryl mono- and dipalmitostearate has no standalone Orange Book listing because it is not an approved active drug product. It therefore has no independent Orange Book patent listing, Hatch-Waxman exclusivity period or Paragraph IV challenge.
Paragraph IV litigation can arise when a generic product uses the excipient in a formulation covered by a listed patent for the active drug product. The legal exposure belongs to the finished medicine and its formulation claims.
Biosimilar risk
Biosimilar competition is not directly relevant. Glyceryl mono- and dipalmitostearate is a small-molecule excipient and is not a biologic reference product. Its demand can still benefit indirectly from biologic-device and injectable formulation development, but the principal market remains oral and topical pharmaceuticals.
When does glyceryl mono- and dipalmitostearate lose exclusivity?
It does not have a single drug-style exclusivity date. The commercial position depends on:
- Public-domain chemistry.
- Supplier-specific manufacturing know-how.
- Customer qualification status.
- Technical documentation.
- Formulation-specific patents.
- Quality consistency.
- Regulatory history.
- Geographic availability.
A supplier can lose commercial share without losing a patent if a customer qualifies a second source or adopts another release-modifying excipient. Conversely, a supplier may retain pricing power after any process patent expires if its material remains embedded in validated pharmaceutical formulations.
How strong is the patent estate for this excipient?
The standalone patent estate is weak because the chemical class is established and widely used. The defensible moat is operational rather than patent-based.
| Protection factor |
Assessment |
| Broad composition patent |
Weak |
| Basic manufacturing patent |
Weak to moderate, depending on process specificity |
| Formulation know-how |
Moderate |
| Customer qualification |
Moderate to strong |
| Regulatory documentation |
Moderate |
| Global manufacturing scale |
Moderate |
| Technical support |
Moderate to strong |
| Switching costs |
Moderate |
The strongest commercial barrier is the cost and delay of replacing a qualified excipient in an approved or late-stage product. That barrier is meaningful but not permanent.
What is the financial trajectory through the medium term?
The expected trajectory is moderate volume growth with uneven pricing.
Base case
The base case is low- to mid-single-digit annual growth in pharmaceutical-grade demand, supported by generic modified-release products, contract development activity and continued use in oral solid dosage forms. Revenue growth should exceed volume growth when suppliers shift customers toward higher-purity or application-specific grades.
Upside case
An upside scenario would require wider use in:
- High-drug-load controlled-release systems.
- Solubility-enhancing lipid platforms.
- Continuous manufacturing.
- Specialty multiparticulate products.
- Regional supply-chain diversification.
Under this scenario, technical grades could achieve stronger pricing and margin expansion than commodity E471 products.
Downside case
Downside risks include:
- Substitution by glyceryl behenate, waxes or polymeric matrix formers.
- Generic price compression.
- Reduced development spending for oral controlled-release products.
- Feedstock inflation that cannot be passed through.
- Customer consolidation and supplier bidding.
- Regulatory findings affecting specific grades.
- Increased use of direct-compression excipient blends.
No public company provides sufficient segment disclosure to calculate a reliable standalone EBITDA or revenue forecast for this excipient. Financial analysis should therefore use supplier-level exposure, product mix and production economics rather than a reported market capitalization or company revenue attribution.
What generic launch risks exist?
Generic manufacturers using the excipient face four principal risks.
First, the excipient may alter dissolution when its ester composition or particle size changes. Second, supply qualification can delay regulatory filing or commercial launch. Third, formulation patents may cover the drug-excipient combination even when the excipient itself is unpatented. Fourth, a supplier change can trigger comparative studies and stability work.
The risk is higher for narrow therapeutic index drugs, complex multiparticulates and products with highly sensitive release profiles. It is lower for conventional immediate-release tablets where the material is used mainly as a processing aid.
What geographic markets are most attractive?
North America and Western Europe offer higher pharmaceutical-grade pricing and stronger documentation requirements. India and China offer faster volume growth and lower manufacturing costs, but price competition is more intense. Japan and South Korea have technically demanding pharmaceutical markets with high quality expectations. Latin America, Southeast Asia and the Middle East offer incremental demand through generic drug production and imported excipient distribution.
A supplier seeking durable growth should combine:
- Production near fatty-acid feedstocks.
- Regional inventory.
- Global GMP documentation.
- Dual-site or contingency manufacturing.
- Local regulatory support.
- Technical formulation services.
Key Takeaways
- Glyceryl mono- and dipalmitostearate is primarily a controlled-release and lipid excipient.
- The pharmaceutical market is smaller than the broader E471 and glycerol ester market but has higher pricing and switching costs.
- No reliable standalone public market size or supplier revenue figure exists.
- Demand is supported by generic modified-release drugs, contract manufacturing and oral formulation development.
- Feedstock prices, especially palmitic and stearic acid costs, directly affect margins.
- The chemical itself has limited standalone patent protection.
- Commercial defensibility comes from GMP quality, customer qualification, technical support and formulation know-how.
- Orange Book, Paragraph IV and biosimilar concepts apply only indirectly through finished drug products.
- Medium-term growth is likely to be moderate, with stronger economics in pharmaceutical and specialty grades than in food-grade material.
FAQs About Glyceryl Mono- and Dipalmitostearate
Is glyceryl mono- and dipalmitostearate the same as glyceryl monostearate?
No. Glyceryl monostearate is primarily a stearic-acid glyceride, while glyceryl mono- and dipalmitostearate contains glycerides associated with palmitic and stearic acids. Commercial specifications can overlap, so identity should be confirmed through the supplier’s certificate of analysis and compendial designation.
Can glyceryl mono- and dipalmitostearate be replaced without a new drug application?
Replacement depends on the product, dosage form and regulatory filing. A supplier change may require comparative dissolution, stability studies, quality documentation and regulatory notification. The need for a formal filing depends on the applicable jurisdiction and the significance of the excipient change.
Which excipient competes most directly with glyceryl palmitostearate?
Glyceryl behenate is one of the closest competitors in sustained-release lipid matrices. Ethylcellulose, stearic acid, hydrogenated vegetable oils and waxes can also compete, depending on drug loading, release target and manufacturing process.
Does glyceryl mono- and dipalmitostearate have a dedicated DMF?
Some suppliers may maintain drug master files or equivalent confidential regulatory packages for specific pharmaceutical grades. DMF availability is supplier-specific and should not be inferred from the chemical name or food-additive status.
Is pharmaceutical-grade material materially more profitable than food-grade E471?
Usually, yes. Pharmaceutical-grade products require tighter control, testing, documentation and change management. Those requirements support higher prices, although the smaller market, qualification costs and customer concentration can offset part of the margin advantage.
References
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
European Commission. (2022). EudraLex, Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Part I, Chapter 5: Production. https://health.ec.europa.eu/medicinal-products/eudralex_en
-
European Food Safety Authority. (2021). Re-evaluation of mono- and diglycerides of fatty acids (E 471) as a food additive. EFSA Journal, 19(11). https://doi.org/10.2903/j.efsa.2021.6885
-
United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary, General Chapters and excipient monographs. U.S. Pharmacopeial Convention.
-
Gattefossé. (n.d.). Precirol pharmaceutical excipients. https://www.gattefosse.com/pharmaceuticals/product-finder/precirol/
